feeling worn down a bit; pain in legs, feet pain; headaches; occasional chest pain; This case was reported by a other health professional via other manufacturer and described the occurrence of worn out in a adult female patient who received Flu unspecified (Influenza vaccine) for prophylaxis.   Co-suspect products included epoprostenol sodium powder for infusion (batch number MX005J01P1, expiry date 31st October 2022) for pulmonary arterial hypertension, epoprostenol sodium vial adaptor device administration system (batch number MX005J01P1, expiry date 31st October 2022) for pulmonary hypertension, epoprostenol sodium powder for infusion (batch number MX011J01P1, expiry date 31st May 2023) for pulmonary arterial hypertension, epoprostenol sodium vial adaptor device administration system (batch number MX011J01P1, expiry date 31st May 2023) for pulmonary hypertension, epoprostenol sodium (Flolan) powder for infusion for product used for unknown indication and epoprostenol sodium vial adaptor device administration system (batch number Unk, expiry date unknown) for product used for unknown indication.   The patient's past medical history included gallbladder operation and sinusitis. Concurrent medical conditions included pulmonary arterial hypertension.   On an unknown date, the patient received Influenza vaccine, epoprostenol sodium (intravenous) at an unknown dose and frequency, epoprostenol sodium vial adaptor device, epoprostenol sodium (intravenous) at an unknown dose and frequency, epoprostenol sodium vial adaptor device, Flolan at an unknown dose and frequency and epoprostenol sodium vial adaptor device. On an unknown date, unknown after receiving Influenza vaccine and an unknown time after starting epoprostenol sodium, epoprostenol sodium vial adaptor device, epoprostenol sodium, epoprostenol sodium vial adaptor device, Flolan and epoprostenol sodium vial adaptor device, the patient experienced worn out, leg pain, headache and chest pain. Epoprostenol sodium was continued with no change. Epoprostenol sodium was continued with no change. The action taken with Flolan was unknown. On an unknown date, the outcome of the worn out, leg pain, headache and chest pain were unknown.   It was unknown if the reporter considered the worn out, leg pain, headache and chest pain to be related to Influenza vaccine, epoprostenol sodium, epoprostenol sodium vial adaptor device, epoprostenol sodium, epoprostenol sodium vial adaptor device, Flolan and epoprostenol sodium vial adaptor device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 28-Mar-2022 Reporter's comments: No concomitant medications were reported. After receving Influenza vaccine, on an unspecified date, the patient experienced feeling worn down a bit, pain in legs, feet pain, headaches and occasional chest pain. The dose of epoprostenol sodium was not changed and action taken with influenza vaccine and epoprostenol sodium was not reported.  The reporter provided no causality assessment. Company causality between epoprostenol sodium, and feeling worn down a bit, and pain in legs, feet pain was not related, and between epoprostenol sodium, and headaches, and occasional chest pain was related.